SecBot SecBot
Insider Cluster (2 insiders) ·Filed May 14, 2026

STTK

Shattuck Labs, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago
Insider cluster: 2 insiders, $213K total
Actionable Insight • Neutral

The insider sales are too small to be informative. Focus on the upcoming SL-325 Phase 1 data readout in Q2 2026 as the primary catalyst. The strong cash runway into 2029 reduces near-term financing risk.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
STTK ▲ +14.70% at T+60d
NEUTRAL call +14.70% · α vs SPY +10.18% · entry $6.26 → $7.18
Entry = T+0 close
May 14, 2026
via day close
T+1d
-4.63%
call -4.63% · α -4.57%
$5.97
settled 5mo ago
T+5d
-2.56%
call -2.56% · α -3.52%
$6.10
settled 5mo ago
T+20d
-26.04%
call -26.04% · α -28.16%
$4.63
settled 5mo ago
T+60d
+14.70%
call +14.70% · α +10.18%
$7.18
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Two STTK insiders (CMO and CTO) sold a combined $212K in open-market sales on May 12, 2026, following the Q1 earnings release that showed a slightly better-than-expected net loss but no revenue. The sales are modest relative to the $480M market cap (0.04%) and likely reflect routine post-earnings window selling rather than a bearish signal, especially given the company's strong cash runway and upcoming Phase 1 data for SL-325.

Key Financial Metrics

Direction
selling
Total Value
$212.5K
Insiders
2

Key Facts

  • CMO Pandite sold 30,000 shares at $6.61 for $198,300 on May 12, 2026
  • CTO Shukla sold 2,032 shares at $7.01 for $14,244 on May 12, 2026
  • Total open-market sales: $212,544, representing 0.04% of $480M market cap
  • Q1 2026 net loss of -$0.13/share beat consensus of -$0.14; company remains pre-revenue
  • Cash position of $90.4M extends runway into 2029; Phase 1 SL-325 data expected Q2 2026
  • CEO, CFO, and other insiders received non-cash grants/exercises (no economic impact)

Financial Impact

Insider sales of $212,544 represent 0.04% of market cap — trivial relative to company size

dilutioninsider ownership

Risk Factors

  • Pre-revenue biotech with no approved products; pipeline failure risk
  • Insider sales, while small, could accelerate if data disappoints
  • Cash burn rate may increase as Phase 2 trials commence

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-STTK-1779104806581
18 reports for STTK
Performance horizon
38% Hit rate @ T+5 3 of 8 directional calls Went positive at some point 3 of 8 best @ T+20▲ +70.22%Jun 9, 2026
Filters
Rows
Reports for STTK — sortable, filterable
TypeNow
Aug 11, 2026
10w ago
8-K
BULLISH ★ 7/10
$7.18 $7.45▲ +3.76%▲ +4.16%$5.54 (−22.84%)
Aug 11, 2026
10w ago
Press Release
NEUTRAL ★ 5/10
$7.18 $7.45▲ +3.76%▲ +4.16%$5.54 (−22.84%)
Jul 7, 2026
15w ago
Insider Cluster
NEUTRAL ★ 3/10
$6.88 $6.29▼ −8.58%▼ −9.44%$5.54 (−19.48%)
Jul 2, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$7.05 $7.03▼ −0.28%▼ −1.21%$5.54 (−21.42%)
Jun 11, 2026
19w ago
8-K
BEARISH ★ 6/10
$4.18 $4.74▼ −13.40%▼ −12.96%$5.54 (−32.54%)
Jun 11, 2026
19w ago
Institutional Cluster
BEARISH ★ 4/10
$4.18 $4.74▼ −13.40%▼ −12.96%$5.54 (−32.54%)
Jun 11, 2026
19w ago
424B5
BEARISH ★ 6/10
$4.18 $4.74▼ −13.40%▼ −12.96%$5.54 (−32.54%)
Jun 10, 2026
19w ago
Press Release
BEARISH ★ 6/10
$4.13 $4.33▼ −4.84%▼ −1.41%$5.54 (−34.14%)
Jun 9, 2026
19w ago
424B5
BEARISH ★ 6/10
$4.13 $4.33▼ −4.84%▼ −1.41%$5.54 (−34.14%)
Jun 9, 2026
19w ago
8-K
BULLISH ★ 6/10
$4.13 $4.33▲ +4.84%▲ +1.41%$5.54 (+34.14%)
Showing 10 of 18

US Market Status

Market Closed — Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026